AI Tool for Prostate Cancer Diagnosis to be Tested in NHS
Researchers have announced that a new artificial intelligence tool designed to assist in diagnosing prostate cancer and guiding treatment decisions will soon undergo testing in NHS hospitals.
The Vanguard Path study, which is backed by Prostate Cancer UK and spearheaded by the University of Oxford, has a budget of £1.9 million and is set to last three years. This study will evaluate the ArteraAI Prostate Biopsy Assay, utilizing biopsy samples from over 4,000 men.
This AI tool analyzes digitized biopsy images to generate personalized risk scores. In earlier clinical trials, it demonstrated the ability to identify which men with high-risk prostate cancer are most likely to benefit from a medication called abiraterone.
Additionally, trials in the US indicated that it might also aid in predictions for less aggressive prostate cancer, helping to determine which patients could benefit from hormone therapy alongside radiotherapy.
There’s also evidence suggesting that this tool might assist in identifying patients who can be monitored rather than requiring immediate treatment.
Dr. Matthew Hobbs, the director of research at Prostate Cancer UK, expressed optimism about the tool’s potential. He mentioned that once implemented, it could provide consistent decision-making support, regardless of the cancer’s aggressiveness. He noted that similar technology is already in use in the US.
The upcoming study will initially use prostate biopsy samples from men who have been diagnosed and treated for prostate cancer in the past, examining whether the tool’s predictive accuracy holds for UK patients.
The testing will occur at three sites: North Bristol NHS Trust, Oxford University Hospitals NHS Foundation Trust, and NHS Greater Glasgow and Clyde, as participants go through the standard diagnosis pathway for prostate cancer.
“Biopsy analyses will be done, treatment options will be chosen, and the man will commence treatment,” Hobbs explained. “Concurrently, NHS clinicians will receive insights from the tool and will be questioned on whether they would have recommended the same treatment.” He added that part of the study will also consider how the tool influences the timeline from diagnosis to treatment choice.
Experts hope this tool can help minimize both under-treatment and over-treatment of patients.
Prof. Gerhardt Attard from University College London, who contributed to the study on abiraterone but is not directly involved in the trial, highlighted the importance of this research. He pointed out that methods often work well during clinical trials but can face various challenges when applied in real-world settings within the NHS.
Ashley Dalton, the minister for public health and prevention, also praised the trial. He described it as a significant advancement, underscoring the potential of technology to transform lives and improve cancer outcomes. “This is why we’re investing in a digital NHS. By leveraging AI and moving beyond outdated systems, we aim to enhance cancer care—diagnosing earlier, treating more effectively, and improving the overall patient experience,” he added.
